FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Teva Pharmaceuticals Buprenorphine Transdermal System 5 mcg/hour Recall

Buprenorphine Transdermal System 5 mcg/hour, 4 transdermal systems/4 disposal units per…

Teva Pharmaceuticals USA · Parsippany, NJ

Risk level
Class II
Reported by FDA
Oct 7, 2020
Recall ID
D-0003-2021
Check your lot numberHow we source this data

Summary

Teva Pharmaceuticals recalled Buprenorphine Transdermal System 5 mcg/hour starting Sep 4, 2020. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0003-2021 on Oct 7, 2020. Reason: Failed Stability Specifications: Below specification result for buprenorphine release rate. Status: Terminated.

Why it was recalled

Failed Stability Specifications: Below specification result for buprenorphine release rate.

Product description

Buprenorphine Transdermal System 5 mcg/hour, 4 transdermal systems/4 disposal units per carton, Rx Only, Manufactured by: 3M Drug Delivery Systems, 19901 Nordhoff street, Northridge, CA 91324 USA, Manufactured for: Teva Pharmaceuticals USA Inc., North Wales, PA 19454, carton NDC: 0093-3656-40, patch NDC: 0093-3656-21.

Lot numbers, UPCs & expiration codes

Lot # 190017, exp. 02/2021; 190161, exp. 08/2021

Where it was sold

Nationwide in the U.S. and PR

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0003-2021
Classification
Class II
Status
Terminated
Recall initiated
Sep 4, 2020
FDA report date
Oct 7, 2020
Quantity
32,543 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Teva Pharmaceuticals USA

Original FDA data

Every field from FDA enforcement report D-0003-2021, exactly as published.

Show all FDA fields
City
Parsippany
State
NJ
Status
Terminated
Country
United States
Event ID
86379
Address
400 Interpace Pkwy
Code information
Lot # 190017, exp. 02/2021; 190161, exp. 08/2021
Postal code
07054-1120
Report date
Oct 7, 2020
Product type
Drugs
Recall number
D-0003-2021
Classification
Class II
Recalling firm
Teva Pharmaceuticals USA
Product quantity
32,543 cartons
Termination date
Aug 26, 2021
Reason for recall
Failed Stability Specifications: Below specification result for buprenorphine release rate.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Buprenorphine Transdermal System 5 mcg/hour, 4 transdermal systems/4 disposal units per carton, Rx Only, Manufactured by: 3M Drug Delivery Systems, 19901 Nordhoff street, Northridge, CA 91324 USA, Manufactured for: Teva Pharmaceuticals USA Inc., North Wales, PA 19454, carton NDC: 0093-3656-40, patch NDC: 0093-3656-21.
Distribution pattern
Nationwide in the U.S. and PR
Recall initiation date
Sep 4, 2020
Initial firm notification
Letter
Center classification date
Oct 1, 2020

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0003-2021, published Oct 7, 2020. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls